Are Options Traders Bullish on ADAP?
Let daily Option Order Flow show you where stock investors are Bullish and Bearish!!! Receive a FREE daily email of the Market Chameleon Order Flow Sentiment Newsletter.
Market Chameleon

Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

About ADAP

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the bodys own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmunes lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. As of June 30, 2015, 85 patients had been treated with Adaptimmunes NY-ESO TCR therapeutic: 47 under Adaptimmunes IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 150 employees.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADAP is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 294.9 M 2.94941E+08 202 202 0.03% 0.000259037 159 K 159198
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 49.4 M 4.94E+07 86 86 0.01% 0.0001 5 K 4706
ADRU Invesco BLDRS Europe Select ADR Index Fund 13.3 M 1.33E+07 74 74 0.01% 0.00011 2 K 1526
IBB iShares Nasdaq Biotechnology Index Fund 8.1 B 8.0755E+09 191 191 0.05% 0.0005 4.3 M 4285980
UBIO Proshares UltraPro Nasdaq Biotechnology 30.1 M 3.01163E+07 196 196 0.01% 0.000119401 12 K 11968

Wait, Before You Leave...